To flare or not to flare: patients' and rheumatologists' perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis.
Delphine BertrandAnke DeprezMichaël DoumenDiederik De CockSofia PazminoAnja MarchalMarc ThelissenJohan JolyElias De MeystBarbara NeerinckxRené WesthovensPatrick VerschuerenPublished in: Therapeutic advances in musculoskeletal disease (2024)
This study revealed that both stakeholder groups perceived the heterogeneity in recognition of and reaction to a flare as important in influencing the effectiveness of the on-flare retreatment strategy. Moreover, this study identified the benefits and barriers of treating on-flare, which could be informative for daily practice decisions.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- randomized controlled trial
- physical activity
- ejection fraction
- single cell
- chronic kidney disease
- newly diagnosed
- depressive symptoms
- mental health
- peritoneal dialysis
- social support
- systemic lupus erythematosus
- prognostic factors
- diffuse large b cell lymphoma
- disease activity
- patient reported outcomes
- ankylosing spondylitis